A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

doi:10.1183/09031936.02.00269802

HOME

HELP

FEEDBACK

SUBSCRIPTIONS

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

R. Casaburi¹, D.A. Mahler², P.W. Jones³, A. Wanner⁴, G. San Pedro⁵, R.L. ZuWallack⁶, S.S. Menjoge⁷, C.W. Serby⁷ and T. Witek, Jr⁷

¹ Harbor-UCLA Research and Education Institute, Torrance, CA, ² Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁴ University of Miami School of Medicine, Miami, FL, ⁵ Louisiana State University Medical Center, Shreveport, LA, ⁶ St Francis Hospital and Medical Center, Hartford, CT, and ⁷ Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. ³ St George's Hospital, London, UK

CORRESPONDENCE: R. Casaburi, Harbor-UCLA Research and Education Institute, Building RB-2, 1124 W. Carson Street, Torrance, CA, 90502, USA. Fax: 1 310 3289849. E-mail: casaburi@ucla.edu

Keywords: chronic obstructive pulmonary disease, dyspnoea, exacerbations, quality of life, tiotropium

Received: August 9, 2001
Accepted November 2, 2001

This study was supported by Boehringer Ingelheim Pharmaceuticals, Inc.

Currently available inhaled bronchodilators used as therapyfor chronic obstructive pulmonary disease (COPD) necessitatemultiple daily dosing. The present study evaluates the long-termsafety and efficacy of tiotropium, a new once-daily anticholinergicin COPD.

Patients with stable COPD (age 65.2±8.7 yrs (mean±sd),n=921) were enrolled in two identical randomized double-blindplacebo-controlled 1-yr studies. Patients inhaled tiotropium18 µg or placebo (mean screening forced expiratoryvolume in one second (FEV₁) 1.01 versus 0.99 L, 39.1 and38.1% of the predicted value) once daily as a dry powder. Theprimary spirometric outcome was trough FEV₁ (i.e. FEV₁ priorto dosing). Changes in dyspnoea were measured using the TransitionDyspnea Index, and health status with the disease-specific St.George's Respiratory Questionnaire and the generic Short Form36. Medication use and adverse events were recorded.

Tiotropium provided significantly superior bronchodilation relativeto placebo for trough FEV₁ response ( $~$ 12% over baseline) (p<0.01)and mean response during the 3 h following dosing ( $~$ 22%over baseline) (p<0.001) over the 12-month period. Tiotropiumrecipients showed less dyspnoea (p<0.001), superior healthstatus scores, and fewer COPD exacerbations and hospitalizations(p<0.05). Adverse events were comparable with placebo, exceptfor dry mouth incidence (tiotropium 16.0% versus placebo 2.7%,p<0.05).

Tiotropium is an effective, once-daily bronchodilator that reducesdyspnoea and chronic obstructive pulmonary disease exacerbationfrequency and improves health status. This suggests that tiotropiumwill make an important contribution to chronic obstructive pulmonarydisease therapy.

This article has been cited by other articles:

K. F. Rabe
Anticholinergic Drugs for the Treatment of COPD Are Safe... Are They?
Chest, January 1, 2010; 137(1): 1 - 3.
[Full Text] [PDF]

B. Celli, M. Decramer, I. Leimer, U. Vogel, S. Kesten, and D. P. Tashkin
Cardiovascular Safety of Tiotropium in Patients With COPD
Chest, January 1, 2010; 137(1): 20 - 30.
[Abstract] [Full Text] [PDF]

B. Celli, M. Decramer, S. Kesten, D. Liu, S. Mehra, D. P. Tashkin, and on behalf of the UPLIFT Study Investigators
Mortality in the 4-Year Trial of Tiotropium (UPLIFT) in Patients with Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., November 15, 2009; 180(10): 948 - 955.
[Abstract] [Full Text] [PDF]

A. Gavalda, M. Miralpeix, I. Ramos, R. Otal, C. Carreno, M. Vinals, T. Domenech, C. Carcasona, B. Reyes, D. Vilella, et al.
Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile
J. Pharmacol. Exp. Ther., November 1, 2009; 331(2): 740 - 751.
[Abstract] [Full Text] [PDF]

T. Welte, M. Miravitlles, P. Hernandez, G. Eriksson, S. Peterson, T. Polanowski, and R. Kessler
Efficacy and Tolerability of Budesonide/Formoterol Added to Tiotropium in Patients with Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., October 15, 2009; 180(8): 741 - 750.
[Abstract] [Full Text] [PDF]

A. Anzueto and M. Miravitlles
Efficacy of tiotropium in the prevention of exacerbations of COPD
Therapeutic Advances in Respiratory Disease, June 1, 2009; 3(3): 103 - 111.
[Abstract] [PDF]

M Hasegawa, H Makita, Y Nasuhara, N Odajima, K Nagai, Y Ito, T Betsuyaku, and M Nishimura
Relationship between improved airflow limitation and changes in airway calibre induced by inhaled anticholinergic agents in COPD
Thorax, April 1, 2009; 64(4): 332 - 338.
[Abstract] [Full Text] [PDF]

A. M Chen, S. G Bollmeier, and P. M Finnegan
Long-Acting Bronchodilator Therapy for the Treatment of Chronic Obstructive Pulmonary Disease
Ann. Pharmacother., December 1, 2008; 42(12): 1832 - 1842.
[Abstract] [Full Text] [PDF]

M Najafzadeh, C A Marra, M Sadatsafavi, S D Aaron, S D Sullivan, K L Vandemheen, P W Jones, and J M Fitzgerald
Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD
Thorax, November 1, 2008; 63(11): 962 - 967.
[Abstract] [Full Text] [PDF]

D. P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, S. Menjoge, M. Decramer, and the UPLIFT Study Investigators
A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease
N. Engl. J. Med., October 9, 2008; 359(15): 1543 - 1554.
[Abstract] [Full Text] [PDF]

S. Singh, Y. K. Loke, and C. D. Furberg
Inhaled Anticholinergics and Risk of Major Adverse Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis
JAMA, September 24, 2008; 300(12): 1439 - 1450.
[Abstract] [Full Text] [PDF]

K. F. Rabe, W. Timmer, A. Sagkriotis, and K. Viel
Comparison of a Combination of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Moderate COPD
Chest, August 1, 2008; 134(2): 255 - 262.
[Abstract] [Full Text] [PDF]

D Singh, J Brooks, G Hagan, A Cahn, and B J O'Connor
Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD
Thorax, July 1, 2008; 63(7): 592 - 598.
[Abstract] [Full Text] [PDF]

B. R. Celli
Update on the Management of COPD
Chest, June 1, 2008; 133(6): 1451 - 1462.
[Abstract] [Full Text] [PDF]

P. Albert and P. M. A. Calverley
Drugs (including oxygen) in severe COPD
Eur. Respir. J., May 1, 2008; 31(5): 1114 - 1124.
[Abstract] [Full Text] [PDF]

P. T. Diaz, A. S. Bruns, M. E. Ezzie, N. Marchetti, and B. M. Thomashow
Optimizing Bronchodilator Therapy in Emphysema
Proceedings of the ATS, May 1, 2008; 5(4): 501 - 505.
[Abstract] [Full Text] [PDF]

S. Suissa, P. Ernst, K. L. Vandemheen, and S. D. Aaron
Methodological issues in therapeutic trials of COPD
Eur. Respir. J., May 1, 2008; 31(5): 927 - 933.
[Abstract] [Full Text] [PDF]

Y. Oba
Does Tiotropium Reduce Hospitalizations in Chronic Obstructive Pulmonary Disease?
Ann Intern Med, April 15, 2008; 148(8): 626 - 626.
[Full Text] [PDF]

M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al.
Outcomes for COPD pharmacological trials: from lung function to biomarkers
Eur. Respir. J., February 1, 2008; 31(2): 416 - 469.
[Abstract] [Full Text] [PDF]

S D Aaron, D Fergusson, G B Marks, S Suissa, K L Vandemheen, S Doucette, F Maltais, J F Bourbeau, R S Goldstein, M Balter, et al.
Counting, analysing and reporting exacerbations of COPD in randomised controlled trials
Thorax, February 1, 2008; 63(2): 122 - 128.
[Abstract] [Full Text] [PDF]

J. A. Wedzicha, P. M. A. Calverley, T. A. Seemungal, G. Hagan, Z. Ansari, R. A. Stockley, and for the INSPIRE Investigators
The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium Bromide
Am. J. Respir. Crit. Care Med., January 1, 2008; 177(1): 19 - 26.
[Abstract] [Full Text] [PDF]

A. Qaseem, V. Snow, P. Shekelle, K. Sherif, T. J. Wilt, S. Weinberger, D. K. Owens, and for the Clinical Efficacy Assessment Subcommittee
Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physicians
Ann Intern Med, November 6, 2007; 147(9): 633 - 638.
[Abstract] [Full Text] [PDF]

T. J. Wilt, D. Niewoehner, R. MacDonald, and R. L. Kane
Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline
Ann Intern Med, November 6, 2007; 147(9): 639 - 653.
[Abstract] [Full Text] [PDF]

S. Kesten, M. Plautz, C. A. Piquette, M. P. Habib, and D. E. Niewoehner
Premature discontinuation of patients: a potential bias in COPD clinical trials
Eur. Respir. J., November 1, 2007; 30(5): 898 - 906.
[Abstract] [Full Text] [PDF]

H. A. M. Kerstjens, T. A. Bantje, P. B. Luursema, H. E. J. Sinninghe Damste, J. W. de Jong, A. Lee, S. P. C. Wijker, and P. J. G. Cornelissen
Effects of Short-Acting Bronchodilators Added to Maintenance Tiotropium Therapy
Chest, November 1, 2007; 132(5): 1493 - 1499.
[Abstract] [Full Text] [PDF]

D. A. Mahler and G. J. Criner
Assessment Tools for Chronic Obstructive Pulmonary Disease: Do Newer Metrics Allow For Disease Modification?
Proceedings of the ATS, October 1, 2007; 4(7): 507 - 511.
[Abstract] [Full Text] [PDF]

N. A. Hanania and J. F. Donohue
Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease: Bronchodilators
Proceedings of the ATS, October 1, 2007; 4(7): 526 - 534.
[Abstract] [Full Text] [PDF]

D. A. Mahler, L. A. Waterman, J. Ward, C. McCusker, R. ZuWallack, and J. C. Baird
Validity and Responsiveness of the Self-Administered Computerized Versions of the Baseline and Transition Dyspnea Indexes
Chest, October 1, 2007; 132(4): 1283 - 1290.
[Abstract] [Full Text] [PDF]

P. Brand, T. Meyer, T. Weuthen, W. Timmer, E. Berkel, G. Wallenstein, and G. Scheuch
Lung Deposition of Radiolabeled Tiotropium in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease
J. Clin. Pharmacol., October 1, 2007; 47(10): 1335 - 1341.
[Abstract] [Full Text] [PDF]

N. Roche
Where current pharmacological therapies fall short in COPD: symptom control is not enough
Eur. Respir. Rev., September 1, 2007; 16(105): 98 - 104.
[Abstract] [Full Text] [PDF]

D. J. Powrie, T. M. A. Wilkinson, G. C. Donaldson, P. Jones, K. Scrine, K. Viel, S. Kesten, and J. A. Wedzicha
Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD
Eur. Respir. J., September 1, 2007; 30(3): 472 - 478.
[Abstract] [Full Text] [PDF]

M. Meguro, E. A. Barley, S. Spencer, and P. W. Jones
Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire
Chest, August 1, 2007; 132(2): 456 - 463.
[Abstract] [Full Text] [PDF]

B. R. Celli and P. J. Barnes
Exacerbations of chronic obstructive pulmonary disease
Eur. Respir. J., June 1, 2007; 29(6): 1224 - 1238.
[Abstract] [Full Text] [PDF]

R. Siva, R. H. Green, C. E. Brightling, M. Shelley, B. Hargadon, S. McKenna, W. Monteiro, M. Berry, D. Parker, A. J. Wardlaw, et al.
Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial
Eur. Respir. J., May 1, 2007; 29(5): 906 - 913.
[Abstract] [Full Text] [PDF]

Y. Oba
Cost-Effectiveness of Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease
Mayo Clin. Proc., May 1, 2007; 82(5): 575 - 582.
[Abstract] [Full Text] [PDF]

S. D. Aaron, K. L. Vandemheen, D. Fergusson, F. Maltais, J. Bourbeau, R. Goldstein, M. Balter, D. O'Donnell, A. McIvor, S. Sharma, et al.
Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease: A Randomized Trial
Ann Intern Med, April 17, 2007; 146(8): 545 - 555.
[Abstract] [Full Text] [PDF]

CORRECTION
Thorax, April 1, 2007; 62(4): 371 - 371.
[Full Text] [PDF]

J A Wedzicha and J R Hurst
Chronic obstructive pulmonary disease exacerbation and risk of pulmonary embolism
Thorax, February 1, 2007; 62(2): 103 - 104.
[Full Text] [PDF]

V. Brusasco
Reducing cholinergic constriction: the major reversible mechanism in COPD
Eur. Respir. Rev., December 1, 2006; 15(99): 32 - 36.
[Abstract] [Full Text] [PDF]

D. E. O'Donnell
Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance
Eur. Respir. Rev., December 1, 2006; 15(99): 37 - 41.
[Abstract] [Full Text] [PDF]

R. Rodriguez-Roisin
Impacting patient-centred outcomes in COPD: exacerbations and hospitalisations
Eur. Respir. Rev., December 1, 2006; 15(99): 47 - 51.
[Abstract] [Full Text] [PDF]

M. Decramer
Tiotropium as essential maintenance therapy in COPD
Eur. Respir. Rev., December 1, 2006; 15(99): 51 - 57.
[Abstract] [Full Text] [PDF]

S. Kesten, M. Jara, C. Wentworth, and S. Lanes
Pooled Clinical Trial Analysis of Tiotropium Safety
Chest, December 1, 2006; 130(6): 1695 - 1703.
[Abstract] [Full Text] [PDF]

J. E. Heffner
Update in pulmonary medicine.
Ann Intern Med, November 21, 2006; 145(10): 765 - 773.
[Full Text] [PDF]

P. P. Walker, P. Mitchell, F. Diamantea, C. J. Warburton, and L. Davies
Effect of primary-care spirometry on the diagnosis and management of COPD
Eur. Respir. J., November 1, 2006; 28(5): 945 - 952.
[Abstract] [Full Text] [PDF]

F. H. Rutten, M.-J. M. Cramer, J.-W. J. Lammers, D. E. Grobbee, and A. W. Hoes
Heart failure and chronic obstructive pulmonary disease: An ignored combination?
Eur J Heart Fail, November 1, 2006; 8(7): 706 - 711.
[Abstract] [Full Text] [PDF]

R G Barr, J Bourbeau, C A Camargo, and F S F Ram
Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis
Thorax, October 1, 2006; 61(10): 854 - 862.
[Abstract] [Full Text] [PDF]

R. Kessler, E. Stahl, C. Vogelmeier, J. Haughney, E. Trudeau, C.-G. Lofdahl, and M. R. Partridge
Patient Understanding, Detection, and Experience of COPD Exacerbations: An Observational, Interview-Based Study.
Chest, July 1, 2006; 130(1): 133 - 142.
[Abstract] [Full Text] [PDF]

P. W. Jones
Health Status: What Does It Mean for Payers and Patients?
Proceedings of the ATS, May 1, 2006; 3(3): 222 - 226.
[Abstract] [Full Text] [PDF]

D. A. Mahler
Mechanisms and Measurement of Dyspnea in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, May 1, 2006; 3(3): 234 - 238.
[Abstract] [Full Text] [PDF]

P. S. Burge
Prevention of Exacerbations: How Are We Doing and Can We Do Better?
Proceedings of the ATS, May 1, 2006; 3(3): 257 - 261.
[Abstract] [Full Text] [PDF]

E. F. M. Wouters
Approaches to Improving Health Status in Chronic Obstructive Pulmonary Disease: One or Several?
Proceedings of the ATS, May 1, 2006; 3(3): 262 - 269.
[Abstract] [Full Text] [PDF]

K. F. Rabe
Improving Dyspnea in Chronic Obstructive Pulmonary Disease: Optimal Treatment Strategies
Proceedings of the ATS, May 1, 2006; 3(3): 270 - 275.
[Abstract] [Full Text] [PDF]

S Scott, P Walker, and P M A Calverley
COPD exacerbations {middle dot} 4: Prevention
Thorax, May 1, 2006; 61(5): 440 - 447.
[Abstract] [Full Text] [PDF]

P. W. Jones and A. G. N. Agusti
Outcomes and markers in the assessment of chronic obstructive pulmonary disease.
Eur. Respir. J., April 1, 2006; 27(4): 822 - 832.
[Abstract] [Full Text] [PDF]

D. Dusser, M-L. Bravo, P. Iacono, and on behalf the MISTRAL study group
The effect of tiotropium on exacerbations and airflow in patients with COPD.
Eur. Respir. J., March 1, 2006; 27(3): 547 - 555.
[Abstract] [Full Text] [PDF]

D. E. O'Donnell
Is Sustained Pharmacologic Lung Volume Reduction Now Possible in COPD?
Chest, March 1, 2006; 129(3): 501 - 503.
[Full Text] [PDF]

J. A. van Noord, J. L. Aumann, E. Janssens, J. Verhaert, J. J. Smeets, A. Mueller, and P. J. G. Cornelissen
Effects of Tiotropium With and Without Formoterol on Airflow Obstruction and Resting Hyperinflation in Patients With COPD
Chest, March 1, 2006; 129(3): 509 - 517.
[Abstract] [Full Text] [PDF]

R A Stockley, N Chopra, L Rice, and on behalf of the SMS40026 Investigator Group
Addition of salmeterol to existing treatment in patients with COPD: a 12 month study
Thorax, February 1, 2006; 61(2): 122 - 128.
[Abstract] [Full Text] [PDF]

S. I. Rennard, N. Schachter, M. Strek, K. Rickard, and O. Amit
Cilomilast for COPD: Results of a 6-Month, Placebo-Controlled Study of a Potent, Selective Inhibitor of Phosphodiesterase 4
Chest, January 1, 2006; 129(1): 56 - 66.
[Abstract] [Full Text] [PDF]

V Brusasco, R Hodder, M Miravitlles, L Korducki, L Towse, and S Kesten
Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD
Thorax, January 1, 2006; 58(5): 399 - 404.
[Abstract] [Full Text] [PDF]

S. S. Braman
Chronic Cough Due to Chronic Bronchitis: ACCP Evidence-Based Clinical Practice Guidelines
Chest, January 1, 2006; 129(1_suppl): 104S - 115S.
[Abstract] [Full Text] [PDF]

M. Soler
Modulation of airway inflammation to prevent exacerbations of COPD
Eur. Respir. Rev., December 1, 2005; 14(95): 78 - 82.
[Abstract] [Full Text] [PDF]

Poster presentations
Thorax, December 1, 2005; 60(suppl_2): ii53 - ii120.
[Full Text] [PDF]

K. E. Belmonte
Cholinergic Pathways in the Lungs and Anticholinergic Therapy for Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, November 1, 2005; 2(4): 297 - 304.
[Abstract] [Full Text] [PDF]

G. Juan, M. Ramon, J. C. Valia, J. Cortijo, E. Rubio, E. Morcillo, and P. Calverley
Palliative Treatment of Dyspnea With Epidural Methadone in Advanced Emphysema
Chest, November 1, 2005; 128(5): 3322 - 3328.
[Abstract] [Full Text] [PDF]

J. Haughney, M. R. Partridge, C. Vogelmeier, T. Larsson, R. Kessler, E. Stahl, R. Brice, and C-G. Lofdahl
Exacerbations of COPD: quantifying the patient's perspective using discrete choice modelling
Eur. Respir. J., October 1, 2005; 26(4): 623 - 629.
[Abstract] [Full Text] [PDF]

D. E. Niewoehner, K. Rice, C. Cote, D. Paulson, J. A. D. Cooper Jr., L. Korducki, C. Cassino, and S. Kesten
Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator: A Randomized Trial
Ann Intern Med, September 6, 2005; 143(5): 317 - 326.
[Abstract] [Full Text] [PDF]

G. M. Turino
Therapeutic Gains of Prolonged Bronchial Dilatation in Chronic Obstructive Pulmonary Disease
Ann Intern Med, September 6, 2005; 143(5): 386 - 387.
[Full Text] [PDF]

W. Vincken
Bronchodilator treatment of stable COPD: long-acting anticholinergics
Eur. Respir. Rev., September 1, 2005; 14(94): 23 - 31.
[Abstract] [Full Text] [PDF]

F. Maltais, A. Hamilton, D. Marciniuk, P. Hernandez, F. C. Sciurba, K. Richter, S. Kesten, and D. O'Donnell
Improvements in Symptom-Limited Exercise Performance Over 8 h With Once-Daily Tiotropium in Patients With COPD
Chest, September 1, 2005; 128(3): 1168 - 1178.
[Abstract] [Full Text] [PDF]

H. Somand and T. L Remington
Tiotropium: A Bronchodilator for Chronic Obstructive Pulmonary Disease
Ann. Pharmacother., September 1, 2005; 39(9): 1467 - 1475.
[Abstract] [Full Text] [PDF]

P. M. A. Calverley
Long-acting inhaled bronchodilators in COPD: how many drugs do we need?
Eur. Respir. J., August 1, 2005; 26(2): 190 - 191.
[Full Text] [PDF]

J. A. van Noord, J-L. Aumann, E. Janssens, J. J. Smeets, J. Verhaert, B. Disse, A. Mueller, and P. J. G. Cornelissen
Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD
Eur. Respir. J., August 1, 2005; 26(2): 214 - 222.
[Abstract] [Full Text] [PDF]

S. L. Johnston
Overview of Virus-induced Airway Disease
Proceedings of the ATS, August 1, 2005; 2(2): 150 - 156.
[Abstract] [Full Text] [PDF]

J. L. Olin
Tiotropium: An inhaled anticholinergic for chronic obstructive pulmonary disease
Am. J. Health Syst. Pharm., June 15, 2005; 62(12): 1263 - 1269.
[Abstract] [Full Text] [PDF]

P. J. Barnes and R. A. Stockley
COPD: current therapeutic interventions and future approaches
Eur. Respir. J., June 1, 2005; 25(6): 1084 - 1106.
[Abstract] [Full Text] [PDF]

R. Buhl and S. G. Farmer
Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, April 1, 2005; 2(1): 83 - 93.
[Abstract] [Full Text] [PDF]

J Vestbo, R Pauwels, J A Anderson, P Jones, P Calverley, and on behalf of the TRISTAN study group
Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease
Thorax, April 1, 2005; 60(4): 301 - 304.
[Abstract] [Full Text] [PDF]

M Decramer, R Gosselink, M Rutten-Van Molken, J Buffels, O Van Schayck, P-A Gevenois, R Pellegrino, E Derom, and W De Backer
Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004
Thorax, April 1, 2005; 60(4): 335 - 342.
[Abstract] [Full Text] [PDF]

M Decramer, R Gosselink, P Bartsch, C-G Lofdahl, W Vincken, R Dekhuijzen, J Vestbo, R Pauwels, R Naeije, and T Troosters
Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004
Thorax, April 1, 2005; 60(4): 343 - 349.
[Abstract] [Full Text] [PDF]

R. Casaburi, D. Kukafka, C. B. Cooper, T. J. Witek Jr, and S. Kesten
Improvement in Exercise Tolerance With the Combination of Tiotropium and Pulmonary Rehabilitation in Patients With COPD
Chest, March 1, 2005; 127(3): 809 - 817.
[Abstract] [Full Text] [PDF]

N. J. Gross
Tiotropium Bromide
Chest, December 1, 2004; 126(6): 1946 - 1953.
[Abstract] [Full Text] [PDF]

D. A. Mahler, S. Huang, M. Tabrizi, and G. M. Bell
Efficacy and Safety of a Monoclonal Antibody Recognizing Interleukin-8 in COPD: A Pilot Study
Chest, September 1, 2004; 126(3): 926 - 934.
[Abstract] [Full Text] [PDF]

E. R. Sutherland and R. M. Cherniack
Management of Chronic Obstructive Pulmonary Disease
N. Engl. J. Med., June 24, 2004; 350(26): 2689 - 2697.
[Full Text] [PDF]

W.T. McNicholas, P.M.A. Calverley, A. Lee, and J.C. Edwards
Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD
Eur. Respir. J., June 1, 2004; 23(6): 825 - 831.
[Abstract] [Full Text] [PDF]

D.E. O'Donnell, T. Fluge, F. Gerken, A. Hamilton, K. Webb, B. Aguilaniu, B. Make, and H. Magnussen
Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD
Eur. Respir. J., June 1, 2004; 23(6): 832 - 840.
[Abstract] [Full Text] [PDF]

B.R. Celli, W. MacNee, A. Agusti, A. Anzueto, B. Berg, A.S. Buist, P.M.A. Calverley, N. Chavannes, T. Dillard, B. Fahy, et al.
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
Eur. Respir. J., June 1, 2004; 23(6): 932 - 946.
[Full Text] [PDF]

S. Spencer, P.M.A. Calverley, P.S. Burge, and P.W. Jones
Impact of preventing exacerbations on deterioration of health status in COPD
Eur. Respir. J., May 1, 2004; 23(5): 698 - 702.
[Abstract] [Full Text] [PDF]

A. Hasani, N. Toms, J. E. Agnew, M. Sarno, A. J. Harrison, and P. Dilworth
The Effect of Inhaled Tiotropium Bromide on Lung Mucociliary Clearance in Patients With COPD
Chest, May 1, 2004; 125(5): 1726 - 1734.
[Abstract] [Full Text] [PDF]

R. A. Pauwels
Similarities and Differences in Asthma and Chronic Obstructive Pulmonary Disease Exacerbations
Proceedings of the ATS, April 1, 2004; 1(2): 73 - 76.
[Abstract] [Full Text] [PDF]

P. M. A. Calverley
Reducing the Frequency and Severity of Exacerbations of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, April 1, 2004; 1(2): 121 - 124.
[Abstract] [Full Text] [PDF]

J.B. Oostenbrink, M.P.M.H. Rutten-van Molken, M.J. Al, J.A. Van Noord, and W. Vincken
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease
Eur. Respir. J., February 1, 2004; 23(2): 241 - 249.
[Abstract] [Full Text] [PDF]

D. Turck, W. Weber, R. Sigmund, K. Budde, H.-H. Neumayer, L. Fritsche, K.-L. Rominger, U. Feifel, and T. Slowinski
Pharmacokinetics of Intravenous, Single-Dose Tiotropium in Subjects with Different Degrees of Renal Impairment
J. Clin. Pharmacol., February 1, 2004; 44(2): 163 - 172.
[Abstract] [Full Text] [PDF]

M. Cazzola and M. G. Matera
Long-Acting Bronchodilators Are the First-Choice Option for the Treatment of Stable COPD
Chest, January 1, 2004; 125(1): 9 - 11.
[Full Text] [PDF]

D. P. Tashkin and C. B. Cooper
The Role of Long-Acting Bronchodilators in the Management of Stable COPD
Chest, January 1, 2004; 125(1): 249 - 259.
[Abstract] [Full Text] [PDF]

N. K. Leidy, S. I. Rennard, J. Schmier, M. K. C. Jones, and M. Goldman
The Breathlessness, Cough, and Sputum Scale: The Development of Empirically Based Guidelines for Interpretation
Chest, December 1, 2003; 124(6): 2182 - 2191.
[Abstract] [Full Text] [PDF]

B. R. Celli
A 62-Year-Old Woman With Chronic Obstructive Pulmonary Disease
JAMA, November 26, 2003; 290(20): 2721 - 2729.
[Full Text] [PDF]